Privately held company focused on developing and marketing first-in-class regenerative therapies for osteoarthritis. Our proprietary platform technology harnesses the healing potential of the purinergic system which plays a critical role in maintaining cartilage homeostasis. Our lead product is a proprietary formulation for regenerating cartilage in joints with established osteoarthritis, targeting a rapidly growing joint preservation market. Our goal is to offer patients a disease modifying therapy with uncompromising efficacy relative to existing technologies. By developing this disease modifying therapy, we will significantly improve clinical outcomes and patient quality of life, and reduce the total health care delivery costs associated with regenerative medicine.